AR041407A1 - Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento - Google Patents

Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento

Info

Publication number
AR041407A1
AR041407A1 ARP030103517A ARP030103517A AR041407A1 AR 041407 A1 AR041407 A1 AR 041407A1 AR P030103517 A ARP030103517 A AR P030103517A AR P030103517 A ARP030103517 A AR P030103517A AR 041407 A1 AR041407 A1 AR 041407A1
Authority
AR
Argentina
Prior art keywords
inn
seq
treatment
oligonucleotides
androgen receptor
Prior art date
Application number
ARP030103517A
Other languages
English (en)
Inventor
Rogers Maria Carolina Alvarez
Maria Eugenia Balana
Nestor Alberto Kerner
Original Assignee
Nestor Alberto Kerner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestor Alberto Kerner filed Critical Nestor Alberto Kerner
Priority to ARP030103517A priority Critical patent/AR041407A1/es
Priority to DE602004019481T priority patent/DE602004019481D1/de
Priority to US10/948,781 priority patent/US20060009429A1/en
Priority to EP04022696A priority patent/EP1518928B1/en
Priority to ES04022696T priority patent/ES2322583T3/es
Priority to AT04022696T priority patent/ATE423201T1/de
Publication of AR041407A1 publication Critical patent/AR041407A1/es
Priority to US12/698,055 priority patent/US20100311813A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Se describen oligonucleótidos antiandrógenos aptos para el tratamiento de la caída del cabello y enfermedades de la piel relacionadas con el metabolismo de los andrógenos. Los oligonucleótidos tienen las siguientes secuencias:§ INN-18.1 (SEC ID Ns 1): 5`CATTGGTGAAGGATCGCC 3`; § INN-24 (SEC ID Ns 2): 5`CAATCATTTCTGCTGGCG 3; § INN-71 (SEC ID Ns 3): 5` GGCCTTCTTCGGCTGTGAAG 3`; § INN-72 (SEC ID Ns4): 5` CACACGGTCCATACAACTGG 3`;§ INN-18.2 (SEC ID Ns 5): 5`GGCGAAGTAGAGCATCCT 3`; § INN-24.1 (SEC ID Ns 6); 5`TGGCGCACAGGTACTTCT 3`; § INN-73 (SEC ID Ns 7): 5`CCACCACCACCACACGG 3`; § INN-76 (SEC ID Ns 8): 5`GCCGCCACCACCCCCACC 3`. Estos Principios activos anti-androgénicos son muy específicos para alcanzar su blanco molecular, que se encuentra especialmente circunscripto al sitio de aplicación, principalmente al receptor de andrógenos en la piel y cuero cabelludo de humanos tratados. Los oligonucleótidos descriptos inhiben la expresión del receptor de andrógenos a concentraciones muy bajas en cultivos celulares primarios de la piel y el folículo piloso a través de un mecanismo de acción que implica alcanzar e hibridar con regiones específicas del mARN del RA, de ese modo se activa la digestión por RNasa H del mARN del receptor de andrógeno y en consecuencia se inhibe la traducción de éste último. Se describen también composiciones farmacéuticas y/o cosméticas administrables en forma tópica que contienen los oligonucleótidos. Uso de los oligonucleótidos antiandrógenos y método de tratamiento.
ARP030103517A 2003-09-26 2003-09-26 Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento AR041407A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ARP030103517A AR041407A1 (es) 2003-09-26 2003-09-26 Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
DE602004019481T DE602004019481D1 (de) 2003-09-26 2004-09-23 Antiandrogen-Oligonukleotide zur Behandlung von Androgen-verwandten Hautkrankheiten, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen und deren Verwendung
US10/948,781 US20060009429A1 (en) 2003-09-26 2004-09-23 Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method
EP04022696A EP1518928B1 (en) 2003-09-26 2004-09-23 Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method
ES04022696T ES2322583T3 (es) 2003-09-26 2004-09-23 Oligonucleotidos anti-androgenos utilizables en el tratamiento de trastornos dermatologicos relacionados con el metabolismo de los androgenos, sus composiciones farmaceuticas, sus usos y metodo de tratamiento.
AT04022696T ATE423201T1 (de) 2003-09-26 2004-09-23 Antiandrogen-oligonukleotide zur behandlung von androgen-verwandten hautkrankheiten, diese verbindungen enthaltende pharmazeutische zusammensetzungen und deren verwendung
US12/698,055 US20100311813A1 (en) 2003-09-26 2010-02-01 Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP030103517A AR041407A1 (es) 2003-09-26 2003-09-26 Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento

Publications (1)

Publication Number Publication Date
AR041407A1 true AR041407A1 (es) 2005-05-18

Family

ID=34140109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103517A AR041407A1 (es) 2003-09-26 2003-09-26 Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento

Country Status (6)

Country Link
US (2) US20060009429A1 (es)
EP (1) EP1518928B1 (es)
AR (1) AR041407A1 (es)
AT (1) ATE423201T1 (es)
DE (1) DE602004019481D1 (es)
ES (1) ES2322583T3 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055648A1 (es) * 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
EP4289965A3 (en) * 2016-02-12 2024-02-21 CureVac SE Method for analyzing rna
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
US12067151B2 (en) 2019-04-30 2024-08-20 Enya Inc. Resource-efficient privacy-preserving transactions
US10635837B1 (en) 2019-04-30 2020-04-28 HealthBlock, Inc. Dynamic data protection
CN115721716B (zh) * 2022-07-13 2024-06-14 苏州翊鹏医药科技有限公司 Mdh2抑制剂在雄激素性脱发治疗中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US5556956A (en) * 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
EP0851919A1 (en) * 1995-09-20 1998-07-08 University of Massachusetts Worcester Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US6489163B1 (en) * 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
US6784291B2 (en) * 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
DE10141443B4 (de) * 2001-08-23 2007-02-01 Christos C. Prof. Dr. Zouboulis Verwendung von molekularbiologisch hergestellten, nicht-viralen Wirkstoffen zur Behandlung der Akne
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna

Also Published As

Publication number Publication date
US20060009429A1 (en) 2006-01-12
DE602004019481D1 (de) 2009-04-02
ATE423201T1 (de) 2009-03-15
US20100311813A1 (en) 2010-12-09
EP1518928A1 (en) 2005-03-30
EP1518928B1 (en) 2009-02-18
ES2322583T3 (es) 2009-06-23

Similar Documents

Publication Publication Date Title
Taylor et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma
JP7323707B2 (ja) 皮膚状態改善活性を有するペプチド、及びその用途
ES2751671T3 (es) Composición cosmética calmante basada en ácido salicílico
JP5570992B2 (ja) 皮膚病又は皮膚病変の治療方法及び組成物
Avsar et al. The effects of argan oil in second-degree burn wound healing in rats
BRPI0519647A2 (pt) métodos para tratar um paciente mamìfero tendo inflamação de tecido oral, e para reduzir a inflamação do tecido oral em um paciente mamìfero
BRPI0416592A (pt) composição para cuidado pessoal contendo uma fase de limpeza e uma fase de benefìcio
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
NZ600499A (en) Hatching fluid enzymes and uses thereof
AR041407A1 (es) Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
WO2016044951A1 (en) Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing
TW201416071A (zh) 具抗菌、調節皮脂分泌及去角質功效之組成物以去除或防治粉刺
EP1074245A3 (en) Composition using mineral salts for therapeutic treatment
ES2939257T3 (es) Péptido con actividad blanqueadora de la piel y uso del mismo
JP2017524724A (ja) アンドロゲン性脱毛症を治療するための、テトラペプチドとグリセリルエステルとの会合体
Lin et al. The role of cytokines/chemokines in an aging skin immune microenvironment
JP5654214B2 (ja) 抑毛剤及び抑毛用皮膚化粧料
GT200000035A (es) Derivados de resorcinol.
BR0311371A (pt) Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento
KR102143542B1 (ko) 플라즈마 활성 배양액을 포함하는 멜라닌 생산용 조성물 및 이의 용도
JP6758279B2 (ja) ケモカインを含む皮膚美白用組成物
US20080241285A1 (en) Compositions and Methods to Treat Alopecia
JP2008266256A (ja) Ｍｍｐ遺伝子発現促進剤、コラーゲン代謝促進剤、化粧料および医薬ならびにその製造方法
EP2928460B1 (en) Methods for preventing and treating inflammatory skin conditions
KR101354915B1 (ko) 칼로일-펩타이드 및 이를 이용한 피부 외용제 조성물

Legal Events

Date Code Title Description
FG Grant, registration